Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
NCT05009069Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in rectal cancer, sponsored by Roche. Started Mar 2022; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05009069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009069.